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ABSTRACT
Purpose Observational population- based research is 
a very suitable non- invasive method for studies in the 
vulnerable populations of pregnant women and children. 
Therefore, the PHARMO Perinatal Research Network 
(PPRN) was set up as a resource for life course perinatal 
and paediatric research by linking population- based data 
from existing registrations.
Participants From 1999 to 2017, the PPRN captures 
approximately 542 900 pregnancies of 387 100 mothers 
(‘Pregnancy Cohort’). Additionally, mother–child linkage 
is currently available for a quarter of these pregnancies 
(‘Child Cohort’). The PPRN contains preconceptional 
information on maternal healthcare, as well as detailed 
pregnancy and neonatal data, extending into long- term 
follow- up and outcomes after birth for both mother and 
child up to nearly 20 years. It includes linked data from 
different primary and secondary healthcare settings.
Findings to date Through record linkage of the 
Netherlands Perinatal Registry and the PHARMO Database 
Network, we have established a large population- based 
research network including data on demographics, 
medication use, medical conditions and details 
concerning labour, birth and neonatal outcomes. Here, 
we provide an overview of record types available from 
the PPRN, available database follow- up and pregnancy 
characteristics of the PPRN cohorts. The PPRN has been 
used for a number of different pharmacoepidemiological 
studies, for example, to confirm that preterm- born infants 
were more likely than full- term infants to be hospitalised 
or use medication. Similar long- term comparisons 
showed that children born following spontaneous preterm 
labour were at increased risk of neurodevelopmental and 
respiratory conditions. Most recently, the PPRN provided 
important evidence on the trends in use of potentially 
harmful medication during pregnancy.
Future plans The PPRN provides a unique and 
rich data set facilitating large- scale observational 
pharmacoepidemiological perinatal research. The patient- 
level linkage of many different healthcare data sources 
allows for long- term follow- up of mother and child, with 
ongoing annual updates.
INTRODUCTION
Observational population- based research is a 
very suitable non- invasive method for studies in 
the vulnerable populations of pregnant women 
and children. Therefore, the PHARMO Peri-
natal Research Network (PPRN) was set up as 
a resource for life course perinatal and paedi-
atric research by linking population- based 
data from existing registrations. It was initiated 
around 2010 at the PHARMO Institute for Drug 
Outcomes Research in collaboration with Neth-
erlands Perinatal Registry (Perined). At that 
time it was set up to study the relation between 
medication exposure during pregnancy and 
pregnancy outcomes, but the applications of 
the PPRN have extended considerably over the 
years, along with the continuous expansion of 
the underlying databases.
Strengths and limitations of this study
 ► The main strength of the PHARMO Perinatal 
Research Network (PPRN) lies in the ongoing as-
sembly of detailed, population- based, anonymised 
data from existing registrations which makes it an 
invaluable resource for life course perinatal and 
paediatric research.
 ► Evidence from clinical trials is often lacking behind 
for pregnant women and children, as researchers 
are often hesitant to include these subjects due to a 
variety of reasons. Hence, the PPRN provides a very 
suitable, non- invasive method that stays within the 
many risks and objections of studies in the vulner-
able populations of pregnant women and children.
 ► The PPRN covers a considerable proportion of preg-
nancies from 1999 onwards that has been shown 
to reflect true estimates of the Dutch population 
captured in Netherlands Perinatal Registry (Perined), 
ensuring a high level of generalisability.
 ► Data collection periods and catchment areas vary 
between the linked databases and therefore the size 
of the study population depends on the databases 
included.
 ► Currently, we rely on probabilistic linkage methods 
as the number of records that include a social se-
curity number is currently too limited to allow for 
deterministic record linkage between the PHARMO 
Database Network and Perined.
4300.7802.430. P
rotected by copyright.
 on N
ovem
ber 12, 2020 at E
rasm
us M
edical / X
51
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-037837 on 25 S
eptem
ber 2020. D
ow
nloaded from
 
2 Houben E, et al. BMJ Open 2020;10:e037837. doi:10.1136/bmjopen-2020-037837
Open access 
COHORT DESCRIPTION
Setting
The PPRN is a unique linkage of the Perined and the 
PHARMO Database Network (PHARMO). With data 
collection starting in 1999, the linkage of these population- 
based data sources facilitates large- scale observational 
pharmacoepidemiological perinatal research. It contains 
preconceptional information on maternal healthcare 
extending into long- term follow- up and outcomes after 
birth for both mother and child, with ongoing annual 
updates of the routinely collected data.
Data sources
Perined is a nationwide registry in which medical data 
around pregnancy and birth are included from pregnancies 
with a gestational age of at least 16 weeks (including termi-
nated pregnancies and stillborns).1 It is a linked database 
combining medical registries from four professional groups 
that provide perinatal care: general practitioner, midwives, 
gynaecologists and neonatologists/paediatricians. Among 
the items reported are maternal demographics and 
medical conditions, pregnancy complications and details 
concerning labour, birth and neonatal outcomes. Linking 
the records is a complex operation—especially when it 
comes to records that originate from different data sets. 
Probabilistic linkage based on matching data is performed 
in the absence of unique identification of mother and/or 
child. There is a firm basis for deciding whether two records 
describe the same case or have a lot of resemblance. The 
threshold value for such a decision depends on the situ-
ation and is statistically substantiated.2 The established 
registry reflects virtually all deliveries in the Netherlands 
(~99% agreement with the municipal administration), that 
is, including home as well as hospital births. The frequency 
of data collection and processing is four times a year. The 
average lag time of the data is half a year.
PHARMO is a population- based network of databases 
combining subnational data from different primary and 
secondary healthcare settings in the Netherlands. These 
different data sources, including data from general 
practices, inpatient and outpatient pharmacies, clinical 
laboratories, hospitals, the cancer registry, pathology registry 
and perinatal registry, are linked on a patient level through 
validated algorithms.3 Data are retrieved directly from the 
source, that is, the electronic medical records of the health-
care providers who agree to contribute to PHARMO. All 
patients registered at the contributing healthcare providers 
are included, unless the patient requested to opt out. To 
ensure the privacy of the data in the PHARMO Database 
Network, the collection, processing, linkage and anony-
misation of the data are performed by the foundation 
‘Stichting Informatievoorziening voor Zorg en Onderzoek’ 
(STIZON). STIZON is an independent ISO/IEC 27001 
certified foundation, which acts as a trusted third party 
(TTP) between the data sources and the PHARMO Insti-
tute. Detailed information on the methodology and the 
validation of the used record linkage method can be found 
elsewhere.4 5 PHARMO covers approximately a quarter of 
the Dutch population and is shown to be representative of 
the Dutch population with regard to age and sex; however, 
data collection period, catchment area and overlap between 
data sources differ. The PHARMO databases are linked on 
an annual basis, the average lag time of the data is 1 year.
Perined–PHARMO linkage
STIZON also acts as a TTP for the linkage between 
Perined and PHARMO. This specific linkage is primarily 
based on the birth date of the mother and child, their 
gender and their zip codes. In case multiple possible links 
are established, these determinants are supplemented 
with hospital admission records around delivery as well 
as obstetrician or gynaecologist- prescribed medication. 
Furthermore, home codes that indicate mother and child 
live on the same address are used to verify established 
pairs and improve linkage specificity.
Data collection
From 1999 to 2017, the PPRN captures approximately 
542 900 pregnancies of 387 100 mothers for which a 
PHARMO–Perined link could be established (ie, ‘Preg-
nancy Cohort’). Additionally, an individual mother–
child linkage is currently available for a quarter of these 
Figure 1 Schematic overview of data captured in the PHARMO–Perined linked PHARMO Perinatal Research Network (PPRN).
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pregnancies allowing subjects to be followed over time 
up to nearly 20 years after birth and studying associations 
with pregnancy or neonatal- specific outcomes (ie, ‘Child 
Cohort’). A schematic overview of data captured in the 
PPRN for mothers and children and how these two cohorts 
inter- relate is included in figure 1 and table 1. Further char-
acterisation of the PPRN is included in table 2, including 
the total Perined population as a reference, considering 
that only a subsample of the Netherlands is represented 
by the PHARMO Database Network. Figure 2 presents the 
number of pregnancies included in the Pregnancy Cohort 
and Child Cohort by calendar year. Details on the available 
database follow- up for the children included in the Child 
Cohort are presented in figure 3, with end of follow- up 
defined by either end of database registration (ie, the 
patient moves out of the PHARMO catchment area), death 
or end of study period (31 December 2018), whichever 
occurred first.
Patient and public involvement
No patients were involved in the described linkage between 
existing registries providing an anonymous data set.
FINDINGS TO DATE
Through record linkage of Perined and PHARMO, we 
have established a large population- based research network 
including data on demographics, medication use, medical 
conditions, pregnancy complications and details concerning 
labour, birth and neonatal outcomes. The PPRN has been 
used for a number of different pharmacoepidemiological 
studies (see online supplemental appendix 1 for a citation 
list of work published on the PPRN). Its applicability can 
be centred on the mother, the child or both (ie, assessing 
Table 1 Overview of the record types available from the PPRN
Record type Description Data availability
Pregnancy/neonatal Maternal and neonatal characteristics and perinatal care from 
pregnancies with a gestational age of at least 16 weeks captured 
by midwife practices, gynaecologists, paediatricians and 
neonatologists (maintained by Perined).
From 1999 onwards (full coverage 
for PPRN cohorts).
Medication General practitioner or specialist prescribed healthcare products 
including information on type of product, date, strength, dosage 
regimen, route of administration, prescriber specialty and costs 
dispensed by outpatient pharmacy. Inpatient medication available 
for a subcohort.
From 1998 onwards (full coverage 
for PPRN cohorts for outpatient 
medication; inpatient medication 
only for a subcohort).
General practitioner Patient records registered by general practitioners (gatekeeper of 
the Dutch healthcare system) including information on diagnoses 
and symptoms, laboratory test results, general practitioner visits 
and referrals to specialists.
From 2003 onwards (partial 
coverage for PPRN cohorts).
Laboratory tests Results of laboratory tests performed on clinical specimens, 
requested by general practitioners or medical specialists including 
information on date and time of testing, test result, unit of 
measurement and type of clinical specimen.
From 1998 onwards (partial 
coverage for PPRN cohorts).
Hospital admissions Hospital admissions (ie, inpatient hospital records) for more than 
24 hours and admissions for less than 24 hours for which a bed is 
required including information on hospital admission and discharge 
dates, discharge diagnoses and procedures (maintained by the 
Dutch Hospital Data Foundation).12
From 1998 onwards (full coverage 
for PPRN cohorts up to 2015; 
partial coverage for PPRN 
cohorts from 2016 onwards) after 
permission is granted by the Dutch 
Hospital Data Foundation.
Ambulatory care Ambulatory care (ie, outpatient hospital records; eg, by 
paediatrician), including diagnosis, number of visits, involved 
specialist (maintained by the Dutch Hospital Data Foundation).12
From 2016 onwards (partial 
coverage for PPRN cohorts) after 
permission is granted by the Dutch 
Hospital Data Foundation.
Pathology reports Data on excerpts of histological, cytological and autopsy 
examinations, obtained through linkage with the national Pathology 
Registry13 (maintained by the PALGA Foundation).
From 1998 onwards (full coverage 
for PPRN cohorts) after permission 
is granted by the PALGA 
Foundation.
Malignancies Data on all newly diagnosed cancer cases including information 
on cancer diagnosis, tumour staging, tumour site, morphology 
and initial treatment, obtained through linkage with the national 
Netherlands Cancer Registry14 (maintained by the Netherlands 
Comprehensive Cancer Organisation).
From 1998 onwards (full coverage 
for PPRN cohorts) after permission 
is granted by the Netherlands 
Comprehensive Cancer 
Organisation.
PPRN, PHARMO Perinatal Research Network.
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the association between maternal characteristics and child 
outcomes). As an example, medication use during first year 
of life and hospital admission rates have been assessed and 
compared between premature and term infants.6 Preterm- 
born infants were up to two times more likely than full- term 
infants to be hospitalised or use medication, especially 
related to respiratory disease. Similar long- term compar-
isons of morbidities and healthcare utilisation have been 
made which showed that children born following sponta-
neous preterm labour (irrespective of gestational age at 
delivery) were at increased risk of neurodevelopmental and 
respiratory conditions compared with those from full- term 
labour pregnancies.7 Most recently, data from the PPRN 
have been used to determine population- based trends over 
the last two decades in the use of potentially harmful medi-
cation among pregnant women.8
STRENGTHS AND LIMITATIONS
The main strength of the PPRN lies in the ongoing assembly 
of detailed, population- based, anonymised data from 
existing registrations which makes it an invaluable resource 
for life course perinatal and paediatric research. Evidence 
from clinical trials is often lacking behind for pregnant 
women and children, as researchers are often hesitant to 
include these subjects due to a variety of reasons, including 
the fear of harm to the fetus and threat of legal liability.9 10 
Therefore, the PPRN provides a very suitable, non- invasive 
method that stays within the many risks and objections of 
studies in the vulnerable populations of pregnant women 
Table 2 Pregnancy characteristics in the Pregnancy Cohort and the Child Cohort of the PPRN
PHARMO Perinatal Research Network 
(PPRN) 1999–2017
Perined 1999–
2017 (reference)
Pregnancy Cohort Child Cohort Total population
Pregnancies (n) ~542 900 ~126 200 ~3 200 000
Mothers (n) ~387 100 ~101 400 –
Maternal characteristics
  Age at delivery (mean±SD; years) 31.0±4.8 30.8±4.7 31.0±4.9
  Nulliparous (%) 46 57 47
  Dutch ethnicity (%) 79 84 79
  Database history before delivery (mean±SD; years) 6.0±4.3 6.1±4.3 –
  Database follow- up after delivery (mean±SD; years)* 7.9±5.0 7.7±4.7 –
Infant characteristics
  Male sex (%) 51 53 51
  Gestational age at birth (mean±SD; weeks) 39.1±3.5 39.2±2.7 39.3±2.3
  Preterm birth (%) 8 7 8
  Multiple birth (%) 2 <0.5 4
  Database follow- up after birth (mean±SD; years)* 7.8±4.7 7.8±4.7 –
*Current censoring: 31 December 2018.
Figure 2 Number of pregnancies included in the Pregnancy 
Cohort and Child Cohort by calendar year.
Figure 3 Proportion and number of children included in the 
PHARMO Perinatal Research Network (PPRN) Child Cohort, 
with age in years at end of follow- up (current censoring: 31 
December 2018).
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and children. The PPRN covers a considerable proportion 
of pregnancies from 1999 onwards that has been shown 
to reflect true estimates of the Dutch population captured 
in Perined,11 ensuring a high level of generalisability. The 
patient- level linkage of many different healthcare data 
sources provides a very rich data set allowing long- term 
follow- up of mother and child, with data continuously 
being collected.
The PPRN brings together data from various sources. 
Data collection periods and catchment areas vary between 
these databases and therefore the size of the study popu-
lation depends on the databases included. The 542 900 
pregnancies linked in the data cut up to 2017 allow for 
assessment of drug use during the 9- month preconcep-
tion, pregnancy and 9- month postpartum periods. Inclu-
sion of other databases (eg, general practitioner records 
or hospital admissions) will reduce the cohort size. As with 
any database, identification of medical events is limited to 
data that are captured as part of the medical records or 
other linked data sources in daily clinical practice. These 
data are not primarily collected for research purposes and 
rely on appropriate diagnostic coding. Also, the lag time 
for the PHARMO–Perined linked data to become avail-
able is currently approximately 1 year. Furthermore, the 
number of records that include a social security number 
is currently too limited to allow for deterministic record 
linkage between PHARMO and Perined. This availability 
is steadily increasing and will in the future improve the 
ability to differentiate between siblings in case of multiple 
birth pregnancies, which are now under- represented in the 
Child Cohort. The current linkage methods particularly 
gain a high specificity, and including these unique patient 
identifiers the sensitivity is expected to increase further 
as well. The seeming under- representation of multiple 
births in the Pregnancy Cohort is caused by the fact that 
the presented reference proportion for the total Perined 
population includes all pregnancies (including terminated 
pregnancies and stillborns); however, comparisons by 
gestational age indeed show agreement between the two 
(data not presented). Furthermore, the higher propor-
tion of nulliparous women in the Child Cohort compared 
with the other two cohorts is mainly influenced by families 
more often moving houses shortly after delivery of a second 
child compared with their first child, and due to the new 
address it is less likely that the child can be traced back in 
the PHARMO Database Network.
COLLABORATION
Access to the PPRN is, by governance regulations of the 
data collection and contractually agreed between the 
PHARMO Institute and Perined, restricted to researchers 
of the PHARMO Institute, Perined and academic affiliates. 
Academic affiliates from universities, hospitals or other 
research institutes are encouraged to apply for access to the 
anonymised data for scientific study purposes. The data are 
handled in accordance with data protection, privacy regu-
lations and ISO certification schemes. Each data request 
is checked against these policies and requires permission 
of the applicable compliance and privacy boards of both 
PHARMO and Perined. Permission to external databases 
is requested from the database holders (eg, Dutch Hospital 
Data Foundation or PALGA Foundation) on a project basis. 
As it concerns database research with anonymous data, no 
Institutional Review Board or ethics committee approval 
is required. An overview of the variables included in the 
different databases, the terms and conditions and data 
application forms are available on http:// pharmo. nl/ what- 
we- have/ data- request- PHARMO/ and (in Dutch) www. 
perined. nl/ registratie/ faciliteren- onderzoek. Data sets are 
processed in SAS version 9.4 (SAS Institute), but can be 
converted to other data formats. Only a 10% subsample of 
the requested data can be downloaded by the researcher 
from a secure FTP server; access to the full data set can be 
granted to researchers guesting at the PHARMO office.
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